Related Experiment Video

Updated: May 27, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

[Changes of regulatory T cells in the peripheral blood of children with epilepsy]

Chun Li1, Wei-Ning Ma, Hua Wang

  • 1Department of Pediatric Neurology, China Medical University, Shenyang, China.

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|November 22, 2011
PubMed

Insights

Children with epilepsy show lower levels of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) and CD4+ T cells in their blood. These Treg cell changes may play a role in epilepsy development.

Area of Science:

  • Immunology
  • Neurology
  • Cell Biology

Context:

  • Epilepsy is a complex neurological disorder.
  • Regulatory T cells (Tregs) play a crucial role in immune system regulation.
  • Understanding immune system involvement in epilepsy is an active area of research.

Purpose:

  • To investigate the levels of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) in the peripheral blood of children diagnosed with epilepsy.
  • To explore the potential role of these Tregs in the underlying mechanisms (pathogenesis) of epilepsy in pediatric patients.

Summary:

  • This study compared peripheral blood immune cell populations in 41 children with epilepsy and 38 healthy controls using flow cytometry.
  • Results indicated significantly lower percentages of CD4+ CD25+ Foxp3+ Tregs and CD4+ T cells in children with epilepsy compared to healthy controls.
  • Conversely, children with epilepsy exhibited higher percentages of CD8+ T cells, natural killer (NK) cells, and B cells.

Impact:

  • The findings suggest that an abnormal percentage of CD4+ CD25+ Foxp3+ Tregs in peripheral blood could be implicated in the pathogenesis of epilepsy.
  • This research highlights a potential link between immune dysregulation and epilepsy, opening avenues for further investigation into immunomodulatory therapies.
Abstract

More Related Videos

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice07:17

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice

Published on: June 22, 2016

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...